
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is the undisputed pioneer in the underpenetrated $100B MCED market and is actively building a self-pay market and laying the groundwork for broad institutional adoption. Their Q1 beat with 56,000 Galleri tests and $40.8M in revenue indicates strong demand for their breakthrough multi-cancer early detection blood test, and their guidance conservatism reflects uncertainty rather than lack of potential. With upcoming catalysts including ASCO data drop and FDA approval, and a favorable risk/reward profile, GRAIL is a strong buy in the MCED market.
Bears say
GRAIL is facing significant pressures on its top line, with a decline in average selling prices and increased volume discounts leading to a marginal beat on Q1 revenues. Despite impressive growth in the number of prescribers in the first quarter, the company's wide range outlook for the rest of the year points to uncertainty in FDA approval and potential challenges in securing Medicare reimbursement. Additionally, the extensive and complex process of gathering data for its cancer detection technology may pose operational risks and impact the company's ability to meet expectations.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares